For biopharmaceutical innovators evaluating a China microbial CRDMO for large-scale fermentation services, the search typically centers on a few core concerns: Can the partner scale fermentation reliably from lab to commercial volumes? Does it have proven regulatory experience across global markets? And can it solve the persistent technical problems—low yield, instability, and aggregation—that plague many biologic development programs? Yaohai Bio-Pharma, operating under the full corporate name Yaohai Bio-Pharmaceutical, positions itself as a dedicated answer to these questions through its focus on microbial expression systems rather than generic mammalian platforms.
Corporate Background and Strategic Positioning
Founded in 2010, Yaohai Bio-Pharma has built its business model around a specific industry pain point: mammalian expression systems often suffer from low yields and stability issues, while scFv/Fab fragments frequently experience severe aggregation. Biopharmaceutical manufacturing also carries high costs, and companies pursuing international market entry face complex regulatory hurdles across the US, China, and EU. In response, Yaohai Bio-Pharma defines itself as a Microbial CRDMO (Contract Research, Development, and Manufacturing Organization) that provides a one-stop solution spanning R&D, process development, and GMP manufacturing. Its business coverage extends globally, serving customers in the USA, China, Europe (EU), and Australia.
Fermentation Scale and Manufacturing Infrastructure
For companies specifically seeking large-scale fermentation capability, Yaohai Bio-Pharma’s infrastructure is a central differentiator. The company operates 5 production lines ranging from 50L small-scale to 2,000L large-scale fermentation, delivering a combined 7,500L total drug substance capacity. This is supported by 2 drug product fill-finish lines, enabling an integrated path from fermentation through to finished drug product. Upstream capabilities include fermentation process development and optimization, process scale-up and technology transfer, and QbD- and DoE-based process development. Downstream, the company offers protein separation and purification, including chromatography and ultrafiltration, with scale-up capabilities reaching up to 2,000L fermentation.
These capabilities are reinforced by facility-level assurances: Yaohai Bio-Pharma maintains Triple ISO-certified and EU QP-audited facilities, which support both clinical and commercial manufacturing standards expected by global regulators.
Technical Platforms Addressing Core Industry Pain Points
A defining feature of Yaohai Bio-Pharma’s approach is its specialization in microbial expression rather than mammalian systems. The company’s E. coli expression platform and yeast expression platform are engineered for high-yield microbial production, directly addressing the low-yield and stability issues common in mammalian systems. For antibody fragment development, Yaohai Bio-Pharma has developed proprietary refolding technology specifically to resolve the aggregation challenges frequently seen in scFv/Fab fragments—a problem explicitly identified as an industry pain point in the company’s strategic positioning.
Beyond protein expression, the company has extended its platform into nucleic acid therapeutics. The RNASUP mRNA platform supports mRNA production for research and therapeutic applications, while LNP encapsulation technologies, including SORT LNP and AbLNP, address delivery challenges associated with mRNA therapeutics. Since 2022, this platform has supported over 800 RNA projects for universities and biotechs, illustrating sustained throughput in the nucleic acid segment of the business.
Comprehensive Service Capabilities Across the Development Lifecycle
Yaohai Bio-Pharma’s CRDMO model is structured to cover the full development pathway. In early R&D and process development, services include molecular design and construct development, strain development and cell bank establishment, and upstream/downstream process development. As programs progress, the company supports process scale-up and CMC development, including fermentation and purification scale-up, process characterization, and analytical method development and validation.
For organizations requiring clinical supply, Yaohai Bio-Pharma provides GMP drug substance manufacturing, clinical-stage material supply, quality control, and batch release support, along with drug product manufacturing and sterile fill-finish services for applicable products. On the regulatory side, the company offers CMC documentation and regulatory submission support, process validation, and commercial-scale manufacturing for qualified products.
Quality control is supported by 50+ analytical methods, covering protein identity, purity, concentration, potency, and impurity analysis, along with physicochemical and microbiological testing, stability studies, and specification development—functions that are essential for any large-scale fermentation program seeking consistent batch quality.
Regulatory Track Record Across Multiple Markets
Given the global regulatory complexity cited as an industry pain point, Yaohai Bio-Pharma highlights a track record in US-China dual submissions and Australian filings. Documented cases include a successful US-China dual submission for a biopharmaceutical asset, as well as successful European and Australian regulatory registrations for clinical trials. These cases demonstrate the company’s Global Regulatory Affairs capability extends beyond the China domestic market into multi-region clinical and commercial filings.
Operational Performance and Client Outcomes
Yaohai Bio-Pharma reports a 95% client retention rate, a 98% technology transfer success rate, and a 98% successful project delivery rate. According to the company’s materials, clients see an average of 20% cost savings and 30% time savings compared to other CDMO companies, attributed to the one-stop service model spanning R&D through GMP manufacturing.
In terms of program scale, the company has completed 200+ successful projects, currently supports 9 Phase III clinical projects and 15 Phase II clinical projects, and has supported over 100 IND/Phase I projects. Specific product-line case studies include the production of clinical-grade nanobodies (VHH) achieving what the company describes as ultra-high yield and superior stability, addressing aggregation and yield challenges specific to VHH development.
Product Portfolio Built on Microbial Expression
Yaohai Bio-Pharma’s 15 biologic modalities include recombinant protein, plasmid DNA, nanobody (VHH), vaccines, mRNA, and circRNA. Plasmid DNA production, for instance, is positioned to support AAV vector construction and cell therapy applications through high-purity GMP output. Vaccine manufacturing operates at commercial GMP scale under the same ISO-certified and EU QP-audited facilities. Each modality is delivered through the same integrated CRDMO structure—R&D, process development, GMP manufacturing, quality control, and global regulatory affairs—rather than as isolated services.
Summary

For organizations searching for a China microbial CRDMO for large-scale fermentation services, Yaohai Bio-Pharma’s documented capabilities—spanning 7,500L drug substance capacity, five fermentation production lines up to 2,000L, proprietary refolding technology, multi-region regulatory experience, and a broad modality portfolio—reflect a company built specifically around microbial expression system specialization rather than generalized biologic manufacturing. Its combination of technical platforms, GMP infrastructure, and documented client metrics provides a data-grounded basis for evaluating fermentation-focused CRDMO partnerships.
www.yaohaibio-pharma.com
Yaohai Bio-Pharma